REG - IXICO plc - Notice of Interim Results & Investor Presentation

IXICOAnnouncement

Tue 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250506:nRSF3425Ha&default-theme=true

RNS Number : 3425H  IXICO plc  06 May 2025

IXICO plc

("IXICO", the "Company" or the "Group")

 

Notice of 2025 Interim results and Investor Presentation

 

 

06 May 2025  IXICO plc (AIM: IXI), a global leader in neuroscience imaging,
using its AI-driven platform to help advance drug development in neurological
disorders, confirms it will issue unaudited interim results for the six months
ended 31 March 2025 on Tuesday 20 May 2025.

 

Bram Goorden (CEO) and Grant Nash (CFO) will provide a live presentation to
all existing and potential shareholders relating to the Interim Results and
the Company's progress and ongoing strategy via:

 

The Investor Meet Company platform on 20 May 2025 at 16:30 BST.

The presentation is open to all existing and potential shareholders. Questions
can be submitted pre-event via your Investor Meet Company dashboard up until
19 May 2025, 09:00 BST, or at any time during the live presentation.

 

Investors can sign up to Investor Meet Company for free and add to meet IXICO
PLC via:

 

https://www.investormeetcompany.com/ixico-plc/register-investor
(https://gbr01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.investormeetcompany.com%2Fixico-plc%2Fregister-investor&data=05%7C02%7Cjames.chandler%40ixico.com%7Cfd7b2d98fdf74d5f362108dd8303c4d3%7Cd5a3b5c97a6b4ab9abee3de97e9d4955%7C0%7C0%7C638810774401694753%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=DoWkFpNoX3IapWeeYVz5qD7ikqrU%2Fms5pj7zJgFqfaM%3D&reserved=0)

 

Investors who already follow IXICO PLC on the Investor Meet Company platform
will automatically be invited.

 

A recording of the results presentation will be made available on the Group's
website here: https://ixico.com/investors/company-information/investor-videos/
(https://ixico.com/investors/company-information/investor-videos/)

 

 

For further information please contact:

 

 IXICO plc                                                                  +44 (0) 20 3763 7499
 Bram Goorden, Chief Executive Officer Grant Nash, Chief Financial Officer
 Cavendish Capital Markets Limited                                          +44 (0) 20 7220 0500

 (Nominated Adviser and Sole Broker)
  Giles Balleny / Dan Hodkinson (Corporate Finance)

 Nigel Birks (Healthcare Specialist Sales)

 Harriet Ward (Corporate Broking)

 Michael F Johnson (Sales)

 

 

About IXICO www.IXICO.com (http://www.ixico.com/)

IXICO is a global leader in neuroscience imaging and biomarker analytics,
using its proprietary AI-driven platform to help advance the treatment of
neurological disorders and reduce the uncertainties associated with drug
discovery, development and monitoring.   As a key part of the global
neurological disease research community, the Company has built a global
reputation and 20-year track record as an end-to-end Imaging Contract Research
Organisation (iCRO) working with leading pharma companies, innovative
biotech's, disease consortia and non-profit organisations. The IXICO has
supported hundreds of neurological clinical trials, analysed hundreds of
thousands scans and built an expansive network of expert imaging centres
around the world.

 

The IXICO Platform is tailor-made for neurological disease, reliably
processing data from global trials, precisely measuring key imaging biomarkers
associated with the identification, progression and treatment of diseases such
as Alzheimer's, Huntington's and Parkinson's.  Image data is interrogated by
the Platform and IXICO's expert scientists translating complex data into
clinically meaningful while minimizing data variability and increasing
reproducibility.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORUPUPPAUPAGPA